CLZ-8,678158-55-9

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

CLZ-8

CAS No. : 678158-55-9

MCE 国际站：CLZ-8

产品活性：CLZ-8 (Compound 8) 是具有口服活性的 Mcl-1-PUMA 的抑制剂，K_i 值为 0.3 μM。CLZ-8 在下调 PUMA 依赖的凋亡（apoptosis）的同时还能抑制 Mcl-1 介导的癌细胞抗凋亡作用。

研究领域：Apoptosis

作用靶点：Bcl-2 Family  |  Apoptosis

In Vitro: CLZ-8 (Compound 8) (0-160 μM, 48 h) significantly inhibits PUMA-dependent apoptosis.
CLZ-8 (0-1 μM, 2 h) significantly enhance the irradiated cell viability in a dose-dependent manner, provides significant protection for HUVECs, and inhibits overexpressed PUMA.
CLZ-8 (0-1 μM, 24 h) attenuates the radiation-induced apoptosis.
CLZ-8 (1 μM, 2 h) protects HUVECs from DNA breaks.

In Vivo: CLZ-8 (0-400 mg/kg; i.g.; once) shows powerful anti-radiation effects in mice.

相关产品：Bioactive Compound Library Plus  |  Apoptosis Compound Library  |  Anti-Cancer Compound Library  |  Orally Active Compound Library  |  Anti-Blood Cancer Compound Library  |  Mitochondria-Targeted Compound Library  |  Highly Selective Inhibitors Library  |  Highly Selective Activators Library  |  Cell Death Library  |  MG-132  |  Doxorubicin hydrochloride  |  Bafilomycin A1  |  LY294002  |  Tamoxifen  |  Paclitaxel  |  Y-27632  |  Acetylcysteine  |  Angiotensin II human  |  2-Deoxy-D-glucose  |  Staurosporine  |  Venetoclax  |  SB-431542  |  Actinomycin D  |  Deferoxamine mesylate  |  Bortezomib  |  5-Fluorouracil  |  Trametinib  |  Sorafenib  |  Oxaliplatin  |  Gemcitabine  |  Temozolomide  |  Rotenone  |  Mdivi-1  |  Elesclomol  |  Ruxolitinib  |  Decitabine  |  Navitoclax  |  SP600125  |  MK-2206 dihydrochloride

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds